# BioCorRx Inc. (BICX) · Edgar & Edgarette company card

> BioCorRx (BICX) grew revenue 10301% in FY2025 to $1 million, operating margin -606% against a 2.0% median for specialty outpatient facilities, equity -523% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1443863 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/BICX) · [JSON](https://www.pops4.com/boards/company/BICX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $797,244 |
| Revenue growth, 1 year | 10301.1% |
| Revenue growth per year | 101.6% |
| Operating margin | -606.0% (prior year -66829.8%) |
| Net margin | -440.1% |
| Operating cash flow | −$2M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $139,360 |
| Long-term debt | — |
| Total assets | $2M |
| Total equity | −$11M |
| Equity ÷ assets | -522.7% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -170.43 (distress zone)
- Piotroski F: 5 of 9 (middling)
- Health Harbor boat: Rotting at the dock · four or more warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative (-$2.3M in FY2025); operating loss: a margin of -606.0% in FY2025; revenue is hard to predict: its 80% range is ±45%

## Edgarette's reading

Exposure: revenue $797K (FY2025). Experience: revenue up 10301.1% on the year, up 101.6% a year over 4 years; operating margin -606.0%, up from -66829.8%. Soundness: equity -522.7% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $25.4M and $66.9M next year (method v4.1: its own 3-year record of growth weighed at 40% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $23.8M to $71.7M. A statistical range, not company guidance. Against peers (54 filers, $50M+ revenue, its industry group): operating margin -606.0% against a 2.0% median; growth 10301.1% against 13.0%.

Range logged 2026-09-25, receipt 29aef76358c5333c, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-09-04 ([filing](https://www.sec.gov/Archives/edgar/data/1443863/000147793226005416/0001477932-26-005416-index.htm))

## Recent filings

- 8-K · filed 2026-09-04 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1443863/000147793226005416/0001477932-26-005416-index.htm)
- 10-Q · filed 2026-08-14 · [filing](https://www.sec.gov/Archives/edgar/data/1443863/000147793226005041/0001477932-26-005041-index.htm)
- 10-Q · filed 2026-05-15 · [filing](https://www.sec.gov/Archives/edgar/data/1443863/000147793226003159/0001477932-26-003159-index.htm)
- 8-K · filed 2026-04-02 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1443863/000147793226001957/0001477932-26-001957-index.htm)
- 10-K · filed 2026-03-31 · [filing](https://www.sec.gov/Archives/edgar/data/1443863/000147793226001807/0001477932-26-001807-index.htm)
- 10-Q · filed 2025-11-14 · [filing](https://www.sec.gov/Archives/edgar/data/1443863/000147793225008319/0001477932-25-008319-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001443863.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1443863

## Cite

POPS4, Edgar & Edgarette: BioCorRx Inc. (BICX) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/BICX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.